Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Stifel on Neumora Therapeutics (NMRA): ' it's hard to have much conviction in the mechanism in MDD'
August 7, 2025 10:00 AM EDTStifel analyst Paul Matteis reiterated a Hold rating and $2.00 price target on Neumora Therapeutics (NASDAQ: NMRA).
The analyst comments "We remain Hold rated on NMRA following 2Q25 earnings. Following the KOASTAL-1 failure of navacaprant in MDD, management has taken steps to optimize the... More
